RNF5 (RING Finger Protein 5), also known as RMA1 (RING finger protein MALT1-dependent 1), is a RING-type E3 ubiquitin ligase localized primarily to the endoplasmic reticulum (ER) membrane. This enzyme plays a critical role in endoplasmic reticulum-associated degradation (ERAD), a quality control mechanism that identifies, extracts, and targets misfolded or unfolded proteins for proteasomal degradation. RNF5 has emerged as an important player in neurodegenerative disease pathogenesis, with genetic variants and expression changes implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The protein's function in ubiquitinating aggregation-prone proteins and regulating stress response pathways positions it as both a potential therapeutic target and biomarker for neurodegeneration.
| RING Finger Protein 5 (RNF5) |
|---|
| Gene Symbol | RNF5 |
| Full Name | RING Finger Protein 5 |
| Chromosome | 6p21.33 |
| NCBI Gene ID | [11067](https://www.ncbi.nlm.nih.gov/gene/11067) |
| OMIM | 603419 |
| Ensembl ID | ENSG00000243156 |
| UniProt ID | [Q99969](https://www.uniprot.org/uniprot/Q99969) |
| Protein Family | RING finger E3 ubiquitin ligase family |
| Subcellular Location | Endoplasmic reticulum membrane |
| Associated Diseases | ALS, Parkinson's Disease, Alzheimer's Disease |
¶ Gene Structure and Evolution
The RNF5 gene is located on the short arm of chromosome 6 (6p21.33), within the major histocompatibility complex (MHC) class I region. This strategic genomic location has raised intriguing questions about potential regulatory interactions with immune-related genes. The gene spans approximately 4.2 kb of genomic DNA and consists of 4 exons that encode a protein of 180 amino acids.
The RNF5 locus shows significant evolutionary conservation, with orthologs identified in all vertebrate species and even in some invertebrates. The RING finger domain, which mediates E3 ubiquitin ligase activity, is particularly well-conserved, reflecting the fundamental importance of this enzymatic function in cellular proteostasis.
Multiple transcript variants of RNF5 have been described:
- Variant 1 (canonical): Full-length protein (180 amino acids)
- Variant 2: Alternative splicing in 5' UTR affecting translation efficiency
- Variant 3: Truncated isoform with possible dominant-negative function
¶ Protein Structure and Function
¶ Domain Architecture
RNF5 contains several functional domains essential for its role in ERAD:
- N-terminal RING finger domain: Coordinates two zinc ions and mediates ubiquitin transfer
- Transmembrane domain: Anchors the protein to the ER membrane
- C-terminal extension: Contains regulatory sequences and interaction motifs
The RING finger domain follows the canonical C3H2C3 architecture:
- RING finger: CX2CX(13-17)CX1HX2CX(3-6)HX2C
- Zinc coordination: Eight conserved cysteine/histidine residues coordinate two Zn²⁺ ions
RNF5 functions as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin from an E2 conjugating enzyme to substrate proteins. The reaction proceeds through a thioester intermediate:
- E1 activation: Ubiquitin is activated by ATP-dependent attachment to E1 enzyme
- E2 transfer: Ubiquitin is transferred to the active site cysteine of E2 enzyme
- E3-mediated transfer: RNF5 facilitates ubiquitin transfer from E2 to substrate lysine ε-amino group
- Chain elongation: Additional ubiquitin molecules can be added to form polyubiquitin chains
The substrate specificity of RNF5 is determined by:
- Direct substrate recognition: Binding to specific motifs in target proteins
- Adapter protein interactions: Recruitment through ERAD complex components
- Post-translational modifications: Phosphorylation or oxidation alters substrate recognition
RNF5 targets several disease-relevant substrates:
| Substrate |
Function |
Disease Relevance |
| Misfolded CFTR |
ERAD substrate |
Cystic fibrosis |
| GJA1 (Connexin 43) |
Gap junction protein |
Cardiac disease |
| GJB2 (Connexin 26) |
Gap junction protein |
Deafness |
| SEL1L |
ERAD adaptor |
Protein quality control |
| RAB33B |
Vesicle trafficking |
Autophagy regulation |
¶ Expression and Localization
RNF5 is expressed in virtually all human tissues with highest levels in:
- Brain: Cerebral cortex, hippocampus, substantia nigra, cerebellum
- Heart: Myocardium, cardiac conduction system
- Liver: Hepatocytes, biliary epithelium
- Kidney: Proximal tubules, glomeruli
- Lung: Alveolar epithelium, bronchial mucosa
RNF5 localizes exclusively to the endoplasmic reticulum membrane via its N-terminal transmembrane domain. This ER localization is essential for its function in ERAD, where it surveys the ER lumen and membrane for misfolded proteins. The protein forms discrete clusters that colocalize with ERAD components including SEL1L, HRD1, and USP19.
Within the brain, RNF5 shows distinctive patterns:
- Neurons: High expression in pyramidal neurons, dopaminergic neurons
- Astrocytes: Moderate expression, upregulated in reactive astrocytes
- Microglia: Low baseline expression, increased in activated states
- Oligodendrocytes: Variable expression across white matter regions
ERAD is a multi-step quality control system that maintains ER proteostasis:
- Substrate recognition: Chaperones identify misfolded proteins
- Retrotranslocation: Substrates are extracted from the ER lumen/membrane
- Ubiquitination: RNF5 and other E3 ligases add ubiquitin chains
- Extraction: ATPase complexes pull substrates into the cytoplasm
- Proteasomal degradation: Substrates are degraded by the 26S proteasome
RNF5 functions within the SEL1L-HRD1 ERAD complex:
- SEL1L: Scaffold protein bridging RNF5 to the retrotranslocation channel
- HRD1: E3 ligase that cooperates with RNF5
- Derlin proteins: Channel components for retrotranslocation
- ATPase p97/VCP: Provides energy for substrate extraction
RNF5-mediated ubiquitination serves multiple purposes:
- Proteasomal targeting: Polyubiquitin chains mark substrates for degradation
- ER-associated degradation: Prevents toxic protein accumulation
- Regulation of folding: Couples misfolding to degradation
- Calcium homeostasis: Prevents ER calcium dysregulation
RNF5 has emerged as a significant player in ALS pathogenesis:
- Genetic association: GWAS and sequencing studies have identified RNF5 variants as ALS risk modifiers
- Expression changes: RNF5 is upregulated in ALS motor cortex and spinal cord
- Protein aggregation: RNF5 colocalizes with TDP-43 inclusions in sporadic ALS
- ER stress: RNF5 dysregulation contributes to ER stress in motor neurons
- Protein quality control: Impaired ERAD leads to toxic protein accumulation
The connection between RNF5 and ALS reflects the fundamental importance of ERAD in maintaining proteostasis in motor neurons, which are particularly vulnerable to protein aggregation due to their large size and high protein synthesis requirements.
RNF5 involvement in PD relates to several pathogenic mechanisms:
- Alpha-synuclein clearance: RNF5 may help clear aggregation-prone α-syn
- ER stress response: RNF5 regulates ER stress in dopaminergic neurons
- Mitochondrial quality control: Cross-talk between ERAD and mitophagy
- LRRK2 interaction: RNF5 may modulate LRRK2 pathogenic signaling
- Protein ubiquitination: Altered ubiquitin-proteasome system function
Dopaminergic neurons in the substantia nigra pars compacta show particularly high RNF5 expression, potentially reflecting the need for robust ERAD in these metabolically active neurons.
The role of RNF5 in AD involves multiple pathways:
- APP processing: RNF5 may influence amyloid precursor protein metabolism
- Tau pathology: ER stress induced by tau pathology may dysregulate RNF5
- Synaptic proteins: RNF5 regulates synaptic protein quality control
- Neuroinflammation: RNF5 expression is modulated by inflammatory signals
- Neuronal vulnerability: Regional expression patterns may influence AD progression
RNF5 has been implicated in:
- Frontotemporal dementia: Protein aggregation and ER stress mechanisms
- Huntington's disease: Polyglutamine protein clearance
- Spinocerebellar ataxias: Protein quality control in cerebellar neurons
- Prion diseases: ER stress response to misfolded prion protein
| Disease |
RNF5 Role |
Primary Mechanism |
Evidence |
| ALS |
Risk modifier |
ERAD impairment, TDP-43 |
GWAS, expression |
| PD |
Risk modifier |
α-syn clearance, ER stress |
Expression, functional |
| AD |
Risk modifier |
APP processing, tau |
Expression studies |
| FTD |
Possible modifier |
Protein aggregation |
Limited evidence |
RNF5 interacts with numerous cellular proteins:
ERAD Components:
- SEL1L: Core ERAD adaptor protein
- HRD1: E3 ubiquitin ligase complex
- Derlin-1/2/3: Retrotranslocation channel
- USP19: Deubiquitinase regulating ERAD
Ubiquitin System:
- UBC13/UEV1: E2 conjugating enzyme
- UBCH5A/B: E2 conjugating enzymes
- p62/SQSTM1: Autophagy receptor
- TAX1BP1: Autophagy adaptor
Disease-Related Proteins:
- TDP-43: ALS protein aggregation
- Alpha-synuclein: PD protein aggregation
- LRRK2: PD kinase
- APP: Amyloid precursor protein
RNF5 integrates with several key signaling pathways:
- UPR (Unfolded Protein Response): RNF5 is transcriptionally regulated by PERK, IRE1, ATF6
- NF-κB pathway: RNF5 modulates NF-κB signaling
- ER calcium signaling: RNF5 affects calcium homeostasis
- Autophagy pathway: Cross-talk between ERAD and autophagy
Targeting RNF5 for therapeutic benefit:
-
RNF5 activators: Enhance misfolded protein clearance
- Rationale: Boost ERAD capacity in neurodegeneration
- Challenge: Achieving brain penetration
-
RNF5 inhibitors: In specific contexts
- Rationale: Prevent excessive degradation of beneficial proteins
- Challenge: Understanding which substrates to preserve
-
E2 enzyme modulators: Indirect targeting
- Rationale: Modulate RNF5 activity via E2 selection
- Advantage: Broader specificity
AAV-mediated RNF5 modulation:
- Overexpression: Increase ERAD capacity
- Optimized variants: Engineer enhanced activity
- Cell-type specificity: Target specific neuronal populations
RNF5 modulators may synergize with:
- Proteasome inhibitors: Boost protein clearance
- Autophagy enhancers: Alternative clearance pathways
- ER stress modulators: Improve cellular fitness
- Antioxidants: Reduce oxidative stress
Rnf5 knockout mice are viable but show phenotypes:
- Growth retardation: Reduced body weight
- ER stress: Elevated markers in multiple tissues
- Protein aggregation: Accumulation of misfolded proteins
- Enhanced susceptibility: To proteotoxic stress
Overexpression models:
- Neuronal RNF5 OE: Protects against proteotoxic stress
- Motor neuron RNF5 OE: Modestly improves ALS phenotype
- Brain RNF5 OE: Reduces amyloid pathology in AD models
Zebrafish rnf5 mutants show:
- Developmental abnormalities
- ER stress in neural tissue
- Motor behavior deficits
- Useful for drug screening
RNF5 has potential as both diagnostic and progression biomarker:
- Blood expression: RNF5 mRNA detectable in peripheral blood mononuclear cells
- CSF levels: RNF5 protein in cerebrospinal fluid
- Post-mortem brain: RNF5 expression correlates with disease severity
Monitoring RNF5 may predict treatment response:
- ERAD capacity: RNF5 levels indicate proteostasis capability
- Treatment response: Changes in RNF5 with disease-modifying therapies
- Progression marker: RNF5 expression tracks disease progression
Key research areas for RNF5 in neurodegeneration:
- Substrate identification: What are the primary neuronal substrates?
- Regulation mechanisms: How is RNF5 activity regulated?
- Therapeutic targeting: Can RNF5 be safely modulated?
- Biomarker validation: Is RNF5 a reliable biomarker?
- Animal models: What models best recapitulate human disease?
- Proteomics: Identify RNF5 substrate networks
- Structural studies: RNF5-inhibitor complexes
- CRISPR screening: Identify synthetic lethal partners
- Single-cell analysis: Cell-type specific RNF5 functions
RNF5 connects to multiple NeuroWiki pages: